Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

dorsaVi Ltd to commence sale of ViMove in US following FDA clearance


Monday, 14 Jul 2014 08:00pm EDT 

dorsaVi Ltd:Says that it will commence launch of ViMove in the United States following 510K clearance by the US Food and Drug Administration (FDA) for measuring, recording, and reporting on movement and muscle activity of the lower back / lumbar spine.ViMove consists of wearable sensors that are placed on the body to measure movement and muscle activity.